Developer docs
API playgroundTry for free, no card

Search company profiles

Arcellx

Full company profile

uuid00006d4

Namestring
Arcellx
Legal namestring
Arcellx, Inc.
Websiteurl
arcellx.com
Company typeenum
Public
Founded yearint
2014
Descriptiontext

Arcellx is a clinical-stage biotechnology company that develops engineered cell-based immunotherapies for the treatment of cancer and other serious diseases. The company's lead program is anito-cel (anitocabtagene autoleucel), a BCMA-directed CAR T-cell therapy for relapsed or refractory multiple myeloma built on Arcellx's proprietary D-Domain technology platform, which is also intended to support next-generation in vivo cell therapy applications. Anito-cel had reported Phase 2 iMMagine-1 data showing a 96% overall response rate and a 74% complete response/stringent complete response rate, and held FDA Fast Track, Orphan Drug, and RMAT designations, with a BLA accepted for review and a PDUFA action date of December 23, 2026. Arcellx operated under a co-development and commercialization agreement with Gilead Sciences' Kite Pharma subsidiary, signed in December 2022 and expanded in November 2023 with an $85M upfront payment and a $200M equity investment that extended its runway into 2027. Pre-commercial, Arcellx generated only minimal partnership revenue (approximately $1.65M in Q4 2025; analyst consensus of roughly $12.5M for full-year 2025), and the company was acquired by Gilead Sciences for approximately $7.8 billion in April 2026, with Gilead subsequently eliminating about 87% of the inherited workforce.

Short descriptiontext

Arcellx is a clinical-stage biotechnology company developing engineered CAR T-cell immunotherapies — notably the BCMA-directed anito-cel for multiple myeloma built on its proprietary D-Domain platform — serving relapsed/refractory hematologic cancer patients in partnership with Gilead/Kite.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersRedwood City, United States
HQ citystring
Redwood City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell therapy immunotherapy, CAR T-cell therapy, multiple myeloma treatment, BCMA-directed therapies, engineered cell therapies
Industry3 codes
PRIMARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAA
Cell Therapy Developers (Autologous)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Cell Therapy / Oncology Biologics
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Partnership/Collaboration Revenue
TypeLicensing Royalties
Description

Co-development partnership with Gilead/Kite involving shared costs, profits, and investments. Received $85 million upfront payment and $200 million equity investment from Kite in 2023 expansion.

biospace.com
2Equity Investment
TypeLicensing Royalties
Description

$200 million equity investment from Kite extending operational runway into 2027

biospace.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1CART-ddBCMA
Description

A CAR T-cell therapy for multiple myeloma and lymphoma, co-developed with Gilead's Kite Pharma subsidiary. Also referred to as anito-cel (anitocabtagene autoleucel).

biospace.com
Core offering1 text field

Arcellx is a clinical-stage biotechnology company developing engineered cell-based immunotherapies for cancer and other serious diseases, centered on anito-cel (anitocabtagene autoleucel), a BCMA-directed CAR T-cell therapy for relapsed or refractory multiple myeloma built on its proprietary D-Domain technology platform. The company operated through a strategic co-development and commercialization partnership with Gilead Sciences' Kite Pharma subsidiary for global manufacturing, regulatory, and commercial reach.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 96% overall response rate (ORR) in Phase 2 iMMagine-1 trial
+1 more record
Product overview1 text field

Arcellx is a clinical-stage biotechnology company developing cell therapies for cancer and incurable diseases. The company's portfolio centers on anito-cel (anitocabtagene autoleucel), a BCMA-directed CAR T-cell therapy for multiple myeloma built on its proprietary D-Domain technology platform. The ARC SparX platform supports next-generation cell therapy development. The company operated through a partnership with Gilead's Kite subsidiary until Gilead completed its $7.8 billion acquisition in April 2026, gaining full ownership of the anito-cel therapy and eliminating profit-sharing arrangements.

Product and service3 records
1anito-cel (anitocabtagene autoleucel)
CategoryCell Therapy / Oncology Biologics
Description

Investigational BCMA-directed autologous CAR T-cell therapy for the treatment of relapsed or refractory multiple myeloma, developed using Arcellx's proprietary D-Domain technology. Received FDA Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy (RMAT) designations; BLA accepted with PDUFA action date of December 23, 2026.

2CART-ddBCMA
CategoryCell Therapy / Oncology Biologics
Description

CAR T-cell therapy targeting BCMA for lymphoma and multiple myeloma, advanced through the Gilead/Kite partnership. Referenced as the development program name for anito-cel under the Kite co-development arrangement.

3D-Domain Technology Platform
CategoryCell Therapy Technology Platform
Description

Proprietary D-Domain binder platform that underpins Arcellx's CAR-T pipeline, including anito-cel. The platform enables a novel binder architecture that Gilead identified as a potential foundation for next-generation in vivo cell therapy applications.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-23
Description

Gilead acquired remaining shares of Arcellx for $7.8 billion at $115 per share plus $5 CVR. Gilead previously owned ~11.5% of Arcellx. Deal gives Gilead full control of anito-cel and eliminates profit-sharing, milestone, and royalty obligations. Expected to close Q2 2026.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-11-15
Description

Expanded collaboration in blood cancer treatments including advancing CART-ddBCMA therapy for lymphoma and multiple myeloma. Deal involves $85 million upfront payment and $200 million equity investment from Kite, extending Arcellx's operational runway into 2027.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-12-09
Description

Strategic collaboration to develop and commercialize Arcellx's late-stage product CART-ddBCMA for multiple myeloma. Partnership involves co-development, shared costs, profits, and investments with goal of accelerating patient access to therapy.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Co-developer with Johnson & Johnson of Carvykti (ciltacabtagene autoleucel), a BCMA-directed CAR-T therapy approved for relapsed/refractory multiple myeloma. Direct competitor to Arcellx's anito-cel in the same indication and same target class.

2Bristol Myers Squibb (Celgene)
TypeDirect peer
Description

Markets Abecma (idecabtagene vicleucel), the first FDA-approved BCMA-directed CAR-T therapy for multiple myeloma. Anito-cel will compete head-to-head with Abecma in relapsed/refractory MM.

TypeBroad incumbent
Description

Acquirer of Arcellx and operator of the world's largest dedicated in-house cell therapy manufacturing network; commercializes Yescarta and Tecartus CAR-T therapies. Comparable as the incumbent cell therapy player that validated Arcellx's technology.

TypeOthers
Description

Pioneer of autologous CAR-T therapy with Kymriah (tisagenlecleucel); operates a global cell and gene therapy manufacturing footprint and competes broadly in hematologic oncology cell therapy.

TypeEmerging player
Description

Clinical-stage company developing allogeneic ('off-the-shelf') CAR-T therapies, including BCMA-directed candidates. Comparable to Arcellx in cell therapy modality but differentiated by an allogeneic versus autologous manufacturing approach.

TypeDirect peer
Description

Spun out from bluebird bio, originally co-developed Abecma with BMS and continues to work on next-generation cell therapies for hematologic malignancies, directly overlapping with Arcellx's multiple myeloma focus.

TypeEmerging player
Description

Clinical-stage gene editing company developing gene-edited allogeneic CAR-T therapies, including BCMA-directed candidates. Comparable as a next-generation cell therapy peer pursuing hematologic malignancies.

TypeEmerging player
Description

Clinical-stage allogeneic CAR-T developer using CRISPR-based genome editing; relevant peer for cell therapy modality and hematology/oncology pipeline overlap.

TypeEmerging player
Description

Develops engineered T-cell therapies including TCR-T therapies for solid and hematologic cancers; comparable as a cell therapy developer in oncology with similar regulatory and manufacturing dynamics.

TypeEmerging player
Description

Focused on tumor-infiltrating lymphocyte (TIL) cell therapies for solid tumors with an FDA-approved product; comparable as a commercial-stage cell therapy peer with similar manufacturing complexity and oncology focus.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors25 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Arcellx

Cell Therapy / Oncology Biologicsarcellx.com

Arcellx is a clinical-stage biotechnology company developing engineered CAR T-cell immunotherapies — notably the BCMA-directed anito-cel for multiple myeloma built on its proprietary D-Domain platform — serving relapsed/refractory hematologic cancer patients in partnership with Gilead/Kite.

What Arcellx does

Arcellx is a clinical-stage biotechnology company that develops engineered cell-based immunotherapies for the treatment of cancer and other serious diseases. The company's lead program is anito-cel (anitocabtagene autoleucel), a BCMA-directed CAR T-cell therapy for relapsed or refractory multiple myeloma built on Arcellx's proprietary D-Domain technology platform, which is also intended to support next-generation in vivo cell therapy applications. Anito-cel had reported Phase 2 iMMagine-1 data showing a 96% overall response rate and a 74% complete response/stringent complete response rate, and held FDA Fast Track, Orphan Drug, and RMAT designations, with a BLA accepted for review and a PDUFA action date of December 23, 2026. Arcellx operated under a co-development and commercialization agreement with Gilead Sciences' Kite Pharma subsidiary, signed in December 2022 and expanded in November 2023 with an $85M upfront payment and a $200M equity investment that extended its runway into 2027. Pre-commercial, Arcellx generated only minimal partnership revenue (approximately $1.65M in Q4 2025; analyst consensus of roughly $12.5M for full-year 2025), and the company was acquired by Gilead Sciences for approximately $7.8 billion in April 2026, with Gilead subsequently eliminating about 87% of the inherited workforce.

Arcellx firmographics

Firmographics
Name
Arcellx
Legal name
Arcellx, Inc.
Website
https://arcellx.com
Company type
Public
Founded year
2014
Operating status
Acquired
Headcount range
101–250 employees
Short description
Arcellx is a clinical-stage biotechnology company developing engineered CAR T-cell immunotherapies — notably the BCMA-directed anito-cel for multiple myeloma built on its proprietary D-Domain platform — serving relapsed/refractory hematologic cancer patients in partnership with Gilead/Kite.
Ownership category
akta.pro rank

Arcellx industry classification

Industry
Product category
Cell Therapy / Oncology Biologics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAA
Cell Therapy Developers (Autologous)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Cell therapy immunotherapy
  • CAR T-cell therapy
  • Multiple myeloma treatment
  • BCMA-directed therapies
  • Engineered cell therapies

Where Arcellx is headquartered

Location

Headquarters

HQ city
Redwood City
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Arcellx business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Partnership/Collaboration Revenue: Co-development partnership with Gilead/Kite involving shared costs, profits, and investments. Received $85 million upfront payment and $200 million equity investment from Kite in 2023 expansion.
  2. Equity Investment: $200 million equity investment from Kite extending operational runway into 2027

Go-to-market motion2 records

Distribution channels1 record

Marketing channels1 record

Arcellx product offering

Product offering

Core offering

Arcellx is a clinical-stage biotechnology company developing engineered cell-based immunotherapies for cancer and other serious diseases, centered on anito-cel (anitocabtagene autoleucel), a BCMA-directed CAR T-cell therapy for relapsed or refractory multiple myeloma built on its proprietary D-Domain technology platform. The company operated through a strategic co-development and commercialization partnership with Gilead Sciences' Kite Pharma subsidiary for global manufacturing, regulatory, and commercial reach.

Product overview

Arcellx is a clinical-stage biotechnology company developing cell therapies for cancer and incurable diseases. The company's portfolio centers on anito-cel (anitocabtagene autoleucel), a BCMA-directed CAR T-cell therapy for multiple myeloma built on its proprietary D-Domain technology platform. The ARC SparX platform supports next-generation cell therapy development. The company operated through a partnership with Gilead's Kite subsidiary until Gilead completed its $7.8 billion acquisition in April 2026, gaining full ownership of the anito-cel therapy and eliminating profit-sharing arrangements.

Differentiator

Problem solved

Functional benefit

Brands

  • CART-ddBCMA: A CAR T-cell therapy for multiple myeloma and lymphoma, co-developed with Gilead's Kite Pharma subsidiary. Also referred to as anito-cel (anitocabtagene autoleucel).

Products and services

  • anito-cel (anitocabtagene autoleucel) Investigational BCMA-directed autologous CAR T-cell therapy for the treatment of relapsed or refractory multiple myeloma, developed using Arcellx's proprietary D-Domain technology. Received FDA Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy (RMAT) designations; BLA accepted with PDUFA action date of December 23, 2026.
  • CART-ddBCMA CAR T-cell therapy targeting BCMA for lymphoma and multiple myeloma, advanced through the Gilead/Kite partnership. Referenced as the development program name for anito-cel under the Kite co-development arrangement.
  • D-Domain Technology Platform Proprietary D-Domain binder platform that underpins Arcellx's CAR-T pipeline, including anito-cel. The platform enables a novel binder architecture that Gilead identified as a potential foundation for next-generation in vivo cell therapy applications.

Quantifiable outcome

  • 96% overall response rate (ORR) in Phase 2 iMMagine-1 trial
  • +1 more outcomes

Companies that use Arcellx

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Arcellx technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Arcellx partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Gilead Sciences / Kite PharmacoreStrategic or Co-development Partner · 23 February 2026Gilead acquired remaining shares of Arcellx for $7.8 billion at $115 per share plus $5 CVR. Gilead previously owned ~11.5% of Arcellx. Deal gives Gilead full control of anito-cel and eliminates profit-sharing, milestone, and royalty obligations. Expected to close Q2 2026.
  • Gilead Sciences / Kite PharmacoreStrategic or Co-development Partner · 15 November 2023Expanded collaboration in blood cancer treatments including advancing CART-ddBCMA therapy for lymphoma and multiple myeloma. Deal involves $85 million upfront payment and $200 million equity investment from Kite, extending Arcellx's operational runway into 2027.
  • Gilead Sciences / Kite PharmacoreStrategic or Co-development Partner · 9 December 2022Strategic collaboration to develop and commercialize Arcellx's late-stage product CART-ddBCMA for multiple myeloma. Partnership involves co-development, shared costs, profits, and investments with goal of accelerating patient access to therapy.

Scale indicators7 records

Recent moves8 records

Expansion highlights5 records

Arcellx competitors and assessment

Company assessment

Direct peers

  • Legend Biotech: Co-developer with Johnson & Johnson of Carvykti (ciltacabtagene autoleucel), a BCMA-directed CAR-T therapy approved for relapsed/refractory multiple myeloma. Direct competitor to Arcellx's anito-cel in the same indication and same target class.
  • Bristol Myers Squibb (Celgene): Markets Abecma (idecabtagene vicleucel), the first FDA-approved BCMA-directed CAR-T therapy for multiple myeloma. Anito-cel will compete head-to-head with Abecma in relapsed/refractory MM.
  • 2seventy bio: Spun out from bluebird bio, originally co-developed Abecma with BMS and continues to work on next-generation cell therapies for hematologic malignancies, directly overlapping with Arcellx's multiple myeloma focus.

Broad incumbents

  • Gilead Sciences / Kite Pharma: Acquirer of Arcellx and operator of the world's largest dedicated in-house cell therapy manufacturing network; commercializes Yescarta and Tecartus CAR-T therapies. Comparable as the incumbent cell therapy player that validated Arcellx's technology.

Others

  • Novartis: Pioneer of autologous CAR-T therapy with Kymriah (tisagenlecleucel); operates a global cell and gene therapy manufacturing footprint and competes broadly in hematologic oncology cell therapy.

Emerging players

  • Allogene Therapeutics: Clinical-stage company developing allogeneic ('off-the-shelf') CAR-T therapies, including BCMA-directed candidates. Comparable to Arcellx in cell therapy modality but differentiated by an allogeneic versus autologous manufacturing approach.
  • CRISPR Therapeutics: Clinical-stage gene editing company developing gene-edited allogeneic CAR-T therapies, including BCMA-directed candidates. Comparable as a next-generation cell therapy peer pursuing hematologic malignancies.
  • Caribou Biosciences: Clinical-stage allogeneic CAR-T developer using CRISPR-based genome editing; relevant peer for cell therapy modality and hematology/oncology pipeline overlap.
  • Adaptimmune: Develops engineered T-cell therapies including TCR-T therapies for solid and hematologic cancers; comparable as a cell therapy developer in oncology with similar regulatory and manufacturing dynamics.
  • Iovance Biotherapeutics: Focused on tumor-infiltrating lymphocyte (TIL) cell therapies for solid tumors with an FDA-approved product; comparable as a commercial-stage cell therapy peer with similar manufacturing complexity and oncology focus.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Arcellx social profiles

Digital presence

Arcellx financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Arcellx leadership team

Management profile

Number of profiles

Profiles1 record

Arcellx funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors25 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Arcellx M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Arcellx

What does Arcellx do?

Arcellx is a clinical-stage biotechnology company developing engineered cell-based immunotherapies for cancer and other serious diseases, centered on anito-cel (anitocabtagene autoleucel), a BCMA-directed CAR T-cell therapy for relapsed or refractory multiple myeloma built on its proprietary D-Domain technology platform. The company operated through a strategic co-development and commercialization partnership with Gilead Sciences' Kite Pharma subsidiary for global manufacturing, regulatory, and commercial reach.

Is Arcellx a public or private company?

Arcellx is a public company. It is classified as corporate owned and is currently acquired.

When was Arcellx founded?

Arcellx was founded in 2014. It employs 101 to 250 people.

Where is Arcellx based?

Arcellx is headquartered in Redwood City, United States, in the North America region.

How does Arcellx make money?

Two revenue lines are on record. Partnership/Collaboration Revenue is the primary driver. The others are equity Investment.

Who are Arcellx's main competitors?

Direct peers on record are Legend Biotech, Bristol Myers Squibb (Celgene) and 2seventy bio. Gilead Sciences / Kite Pharma is listed as a broad incumbent. Novartis is listed as an others. Emerging players are Allogene Therapeutics, CRISPR Therapeutics, Caribou Biosciences, Adaptimmune and Iovance Biotherapeutics.

Does Arcellx have an API?

No public API is recorded for Arcellx.

What industry is Arcellx in?

Arcellx's product category is Cell Therapy / Oncology Biologics. Its primary akta.pro industry code is HLAAABAC, CAR-T & TCR-T Therapies, with a secondary code of HLAAABAA, Cell Therapy Developers (Autologous). Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FiercePharmaCEO O’Day tells Fierce how Gilead’s cancer, inflammation expansion has reached ‘critical mass’Gilead CEO Daniel O'Day told Fierce that the company's cancer and inflammation expansion has reached critical mass, with acquisitions like Kite, Immunomedics, and Arcellx. He said future M&A will only complement the foundation laid since 2019, and Gilead is investing $32 billion in the U.S. with no plans to expand in China.FierceBiotechCEO O’Day tells Fierce how Gilead’s cancer, inflammation expansion has reached ‘critical mass’Gilead CEO Daniel O'Day said the company's cancer and inflammation expansion has reached critical mass, citing recent acquisitions of Arcellx, Ouro Medicines, and Tubulis. He noted future M&A will only complement the foundation laid since 2019, and Gilead is investing $32 billion in the U.S. with no plans to expand in China.Insider Trading & Hedge Fund DataGilead’s Core Business Is Accelerating, But Will Its $11 Billion Pipeline Bet Pay Off?Gilead Sciences reported a significant quarterly GAAP loss of $8.45 per share driven by $11.2 billion in acquired research and development expenses related to its acquisitions of Arcellx, Tubulis, and Ouro Medicines. Despite this accounting loss, the company's core commercial portfolio delivered double-digit growth, with HIV sales rising 12% and overall product sales guidance being raised for fiscal year 2026.Phirda超 30 亿美元!2026 年上半年 CAR-T 销售额出炉In H1 2026, five CAR-T drugs generated over $3 billion, with Carvykti leading at $1.254 billion. The market is shifting toward autoimmunity and in vivo CAR-T, with major players acquiring assets. Competition will focus on manufacturing capacity and next-generation platforms.Insider Trading & Hedge Fund DataGilead’s Revenue Is Accelerating, But are its Acquisitions Worth the Cost?Gilead Sciences reported a 10% year-over-year revenue increase to $7.8 billion for fiscal Q2 2026, driven by strong performance in its HIV and oncology portfolios. The company recorded an $11.2 billion loss primarily due to acquired research and development expenses from recent acquisitions of Arcellx, Tubulis, and Ouro Medicines. Despite the net loss, management raised its full-year product sales guidance, citing robust underlying commercial momentum.The Motley FoolGilead Sciences Has Quietly Become One of the Most Underrated Turnaround Stories in Healthcare. Here's Why Wall Street Is Excited.Gilead Sciences reported a 10% year-over-year sales increase in Q2, driven by HIV therapies and oncology drugs, with HIV sales up 12% and PrEP sales exceeding $1 billion. The stock rose over 12% this year, and the company expects $12 billion in free cash flow, supporting its dividend and R&D.AInvestGilead's $11 Billion Charge Is Exactly Why This Is The SetupGilead Sciences reported Q2 2026 results with a headline loss due to an $11.2 billion in-process R&D charge from three acquisitions (Arcellx, Tubulis, and Ouro Medicines), while underlying business performance showed strong acceleration with HIV sales up 12% to $5.7 billion, PrEP sales doubling year-over-year to over $1 billion for the first time, and adjusted EPS rising 13% year-over-year to $2.27. The company raised its full-year HIV growth guidance to 9-10% and lifted overall sales outlook to $29.8-$30.1 billion, with trailing operating cash flow of $12.8 billion and a 34.4% FCF margin. The market is pricing the stock as a skeptical observer of the acquisition strategy, with the stock at $135 (down 14% from its 52-week high), leaving the $11.2 billion investment in early-stage assets as upside optionality pending FDA decisions and integration execution through 2027-2028.BioSpaceGilead Sciences Announces Second Quarter 2026 Financial ResultsGilead Sciences reported Q2 2026 revenue of $7.8 billion, up 10% year-over-year, with diluted loss per share of $(8.45). The company guided full-year 2026 diluted loss per share to $(3.75) to $(3.40), citing $9.08 per share in acquired IPR&D charges. It also announced a Q3 dividend of $0.82 per share.Investing.comGilead earnings loom: Can Yeztugo, Trodelvy offset acquisition costs? By Investing.comGilead Sciences is expected to report a Q2 loss of $7.29 per share on revenue of $7.4 billion on Tuesday, reflecting charges from recent acquisitions including Arcellx, Ouro Medicines, and Tubulis, despite strong momentum from its growth drivers Yeztugo ($166M Q1 sales) and Trodelvy ($402M Q1, up 37% YoY). Analysts will scrutinize whether the company's product portfolio can generate sufficient growth to offset acquisition-related costs, with 22 of 29 analysts maintaining Buy ratings and a consensus price target of $157.15 implying nearly 20% upside.Investing.comGilead earnings loom: Can Yeztugo, Trodelvy offset acquisition costs? By Investing.comGilead Sciences is expected to report a second-quarter loss of $7.29 per share on revenue of $7.4 billion, a sharp reversal from Q1's $2.03 per share profit, as charges from its spring acquisitions of Arcellx, Ouro Medicines, and Tubulis weigh on near-term profitability. Revenue is projected to grow 4.5% year-over-year, with investors focused on whether growth engines Yeztugo (HIV prevention injection) and Trodelvy (oncology drug) can offset the acquisition-related costs. Analysts remain divided on the outlook, with 22 of 29 rating the stock a Buy and a consensus price target of $157.15, though EPS estimates have declined 10% over the past 60 days.